MYCN and neoplasm: MYCN amplification is a known marker of tumor progression and resistance in NB (109), and EVs derived from MYCN-amplified NB (SK-N-BE2) cells were found to impart doxorubicin-resistance to non-MYCN amplified recipient SH-SY5Y cells (89).